BRRIAR lncRNA alters breast cancer risk by modulating interferon signaling in cis and in trans.

ABSTRACT:

Background

Interferons (IFNs) are key cytokines that drive immune responses against infections and cancer, yet few therapies have successfully leveraged IFN signaling for cancer treatment. Long noncoding RNAs (lncRNAs) are emerging as promising therapeutic candidates, but their roles in immune modulation remain largely unexplored. Here, we functionally characterize a breast cancer-associated lncRNA, BRRIAR, which primes the IFN signaling pathway in specific cancer contexts and represents a potential therapeutic strategy for estrogen receptor-positive (ER+) breast cancer.

Methods

BRRIAR expression and subcellular localization were examined using qPCR, in situ hybridization, single-cell RNA sequencing and spatial transcriptomics. BRRIAR target genes were identified through CRI

SUBMITTER: Sivakumaran H 

PROVIDER: S-EPMC12777463 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature